Inventiva S.A Asset Resilience Ratio
Inventiva S.A asset resilience ratio. Inventiva S.A (IVA) has an Asset Resilience Ratio of 52.73% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Inventiva S.A liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Inventiva S.A (2017–2025)
Asset resilience ratio of Inventiva S.A from 2017 to 2025. This chart shows how Inventiva S.A's Asset Resilience Ratio has changed over time. Read Inventiva S.A balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Inventiva S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Inventiva S.A asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €131.56 Million | 52.73% |
| Total Liquid Assets | €131.56 Million | 52.73% |
Asset Resilience Insights
- Very High Liquidity: Inventiva S.A maintains exceptional liquid asset reserves at 52.73% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Inventiva S.A Industry Peers by Asset Resilience Ratio
Compare Inventiva S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Inventiva S.A Asset Resilience Ratio by Year (2017–2025)
Inventiva S.A asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Inventiva S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 52.73% | €131.56 Million ≈ $153.81 Million |
€249.51 Million ≈ $291.70 Million |
-- |
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€118.97 Million ≈ $139.08 Million |
-- |
| 2023-12-31 | 0.10% | €70.00K ≈ $81.84K |
€69.56 Million ≈ $81.32 Million |
-0.80pp |
| 2022-12-31 | 0.90% | €1.05 Million ≈ $1.23 Million |
€116.00 Million ≈ $135.62 Million |
-6.33pp |
| 2021-12-31 | 7.24% | €8.83 Million ≈ $10.32 Million |
€121.98 Million ≈ $142.61 Million |
+1.96pp |
| 2020-12-31 | 5.28% | €7.34 Million ≈ $8.58 Million |
€138.92 Million ≈ $162.41 Million |
+5.28pp |
| 2017-12-31 | 0.00% | €-3.11K ≈ $-3.64K |
€74.37 Million ≈ $86.94 Million |
-- |
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more